236 assets in Ovarian Carcinoma

Larotrectinib

L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-

Lifileucel

Loperamide

Neratinib Maleate

Nilotinib

Osimertinib

Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493

Pegcetacoplan

Rain-32

Relatlimab

Selumetinib

Sotorasib

Tazemetostat

Tetanus Toxoid

Toripalimab

Trametinib

Trastuzumab Deruxtecan

Ulixertinib

Asidna

Clarithromycin

Eribulin

Cdx 1140

Envafolimab

sg001

Taselisib

Tinzaparin

Tislelizumab

Diphenoxylate

Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318

Pumvc3-Higfbp-2 Multi-Epitope Plasmid Dna Vaccine

Spartalizumab

Autologous Natural Killer Cell-Like Ctls

bat8006 for

Cobimetinib

Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide

Mdna11

Surufatinib

Tilt-123

Devimistat

Tolinapant

Xmab808

Azenosertib

Fractalkine Receptor Antagonist Kand567

Sodium Sulfate, Anhydrous

Dordaviprone

gpc3 cd146 car-t cells

Jab-8263

Neoantigen Specific Tcr-T Cell Drug Product

Oc-Dc